J Kuball
Overview
Explore the profile of J Kuball including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
1241
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stuut A, Nijssen C, van der Wagen L, van Rhenen A, Daenen L, Janssen A, et al.
Bone Marrow Transplant
. 2025 Mar;
PMID: 40089614
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) aims to cure patients without inducing severe graft-versus-host disease (GVHD) or relapse. In prospective studies of mostly pediatric patients with haploidentical donors, ex vivo...
2.
Daenen L, van der Wagen L, Bonneville E, Lopez-Corral L, Bukauskas A, Bornhauser M, et al.
Bone Marrow Transplant
. 2025 Feb;
PMID: 39979522
Acute graft-versus-host disease (aGvHD) remains a significant complication of allogeneic hematopoietic cell transplantation, with 40% of patients failing to respond to high-dose steroids. Ruxolitinib has become the standard treatment for...
3.
Wezenaar A, Pandey U, Keramati F, Hernandez-Roca M, Brazda P, Barrera Roman M, et al.
Nat Protoc
. 2025 Feb;
PMID: 39930061
The rise of cellular immunotherapy for cancer treatment has led to the utilization of immune oncology cocultures to simulate T cell interactions with cancer cells for assessing their antitumor response....
4.
Secondino S, Badoglio M, Rosti G, Labopin M, Delaye M, Bokemeyer C, et al.
ESMO Open
. 2024 Sep;
9(9):103692.
PMID: 39241498
Background: Primary mediastinal germ-cell tumors (PMGCTs) account for 1%-3% of all germ-cell tumors (GCTs). Non-seminoma have a poorer prognosis compared to their gonadal counterpart and, according to the International Germ...
5.
Johanna I, Daudeij A, Devina F, Nijenhuis C, Nuijen B, Romberg B, et al.
Immunooncol Technol
. 2024 Jan;
20:100411.
PMID: 38192616
Following successes of authorized chimeric antigen receptor T-cell products being commercially marketed in the United States and European Union, product development of T-cell-based cancer immunotherapy consisting of cell-based advanced therapy...
6.
Comoli P, Pentheroudakis G, Ruggeri A, Koehl U, Lordick F, Mooyaart J, et al.
Ann Oncol
. 2023 Dec;
35(4):404-406.
PMID: 38145867
No abstract available.
7.
Worel N, Ljungman P, Verheggen I, Hoogenboom J, Knelange N, Eikema D, et al.
Bone Marrow Transplant
. 2023 Sep;
58(12):1348-1356.
PMID: 37673982
The COVID-19 pandemic has had a significant impact on medical practices, including the delivery of allogeneic hematopoietic cell transplantation (HCT). In response, transplant centers have made changes to their procedures,...
8.
Meringa A, Hernandez-Lopez P, Cleven A, de Witte M, Straetemans T, Kuball J, et al.
Front Immunol
. 2023 Jul;
14:1159337.
PMID: 37441064
No abstract available.
9.
de Witte M, Mooyaart J, Hoogenboom J, Chabannon C, Malard F, Ruggeri A, et al.
Bone Marrow Transplant
. 2023 Mar;
58(6):719-722.
PMID: 36934148
No abstract available.
10.
Hayden P, Roddie C, Bader P, Basak G, Bonig H, Bonini C, et al.
Ann Oncol
. 2021 Dec;
33(3):259-275.
PMID: 34923107
Background: Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade B-cell lymphoma and mantle...